Other innovations
If your innovation doesn’t fit any of the active categories then this is the place to submit your innovation for feedback and the opportunity for wider adoption across the region.

Ideas (Person centred care)

Innovation 'Elevator Pitch':
Liva Healthcare can reverse chronic lifestyle diseases, such as Type 2 Diabetes through digital lifestyle coaching. Liva is a hybrid model of technology and human intervention that drives long term behaviour and lifestyle changes
Overview of Innovation:
 
Founded in 2014, Liva Healthcare is an innovative digital health coaching platform for scalable lifestyle and disease management.  
  
Winner of 'Health IT Firm of the Year' at the HealthInvestor Awards 2018 and 'Healthtech Innovators of the Year - Europe at the Global Health & Pharma Awards 2018, Liva Healthcare is used by public healthcare, private insurance and pharma companies including NHS England, AXA PPP Healthcare and Copenhagen Municipality.  
  
Liva Healthcare’s platform facilitates ongoing personalised health coaching through an intuitive app, building strong bond between coach, GP and patient. Its focus lies on tackling chronic illnesses, such as Type 2 diabetes, obesity and heart disease, by driving behaviour change.   
   
Currently being used in Denmark, UK and Sweden, the app is multilingual across several languages. It has proven to work efficiently across all socio-economic backgrounds and is capable of engaging groups normally hard to reach. It is based upon nine to 18 months of continuous patient engagement to make new habits and behaviours stick. One coach can manage 500 patients per year simultaneously without the loss of patient outcomes.  
  
Implementation time from get-go is normally within weeks and the platform is available as a white-label SaaS platform, or as a turn-key solution, dependent on client specifications.  
  
Liva Healthcare has offices in Copenhagen, Denmark and London, UK. 

Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
By helping to both prevent and cure chronic lifestyle diseases, Liva consequently relieves the cost pressures on healthcare systems.  Unhealthy lifestyles lead to significant cost pressures on healthcare systems. For example, in the UK it is claimed that Type 2 diabetes costs the National Health Service (NHS) £8.8 billion per year, which equates to almost 9pc of its annual budget and causes 20,000 early deaths per year. In addition, it is estimated that obesity costs the NHS over £5 billion per year.   
 
The platform also allows health professionals to monitor up to 400 patients at the same time. This enables the NHS to save costs as the digital health tool can help patients come off medication. It also drives efficiency by enabling more patients to be monitored.  
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The primary benefit that Liva Healthcare provides patients with is the opportunity make long-term lifestyle changes to diet and exercise, with the help of a personal health coach, that can prevent or remove their lifestyle disease (e.g. Type 2 diabetes, obesity or heart disease).  
 
Liva was designed to help prevent and reverse chronic diseases caused by unhealthy modern lifestyles, such as Type 2 diabetes and heart disease, both of which are often caused and affected by weight gain. The app is based on clinical research that has shown lifestyle interventions can lead to long-term lifestyle change and help patients reduce their risk of the disease or enter remission by losing weight.  
 
For example, Liva Healthcare monitored the progress of 136 patients using its digital healthcare app to prevent and roll back Type 2 diabetes over a nine-month period. Over the period, 82% of the patients (112) lost weight, losing an average of 6.3kg, demonstrating signs of a successful lifestyle intervention.  
Current and planned activity: 
In response to the crisis the NHS chose Liva as one of five providers to tackle Type 2 diabetes using digital innovations. GPs can now refer patients at risk of Type 2 diabetes in North East London, Humber, Coast and Vale to use the Liva app. Patients are given a personal health coach and an app to help monitor and track their health goals. The app is based on strong evidence that has shown lifestyle interventions, delivered digitally, can lead to long term lifestyle change and help patients with, or at risk of, Type 2 diabetes reduce their risk of the disease or enter remission. Liva holds the firm belief that prevention is better than cure. Though, in many instances, its platform has been proven to facilitate both. 
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Simon Pickup 01/10/2018 - 14:47 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
People living with dysphagia - swallowing difficulty - need drinks that flow slowly.
We are to help them make Slõ Drinks for all their healthcare needs.
Overview of Innovation:
For people with dysphagia, ordinary drinks like you and I have flow to fast for them to cope with.
As a result they choke when they drink, which can lead to aspiration pneumonia, malnutrition and readmission.

To prevent this they must make all their drinks flow slowly and at specific speeds. This is done by adding thickener using a scoop. However, it is very difficult to add the right amount with a scoop and make every drinks safe to swallow.

We have therefore taken all the drinks someone could need or want, calculated the amount required and put that in a sachet. Then sachet contents are simply mixed with the volume of liquid we specify to change drinks for hydration into Slõ Juice, Slõ Tea or Slõ Fizzy. Drinks for medication such as soluble laxatives into Slõ Solulax and drinks for relaxing with into Slõ Wine, Slõ Beer and Slõ Cider.

Oral Nutritional Supplements (ONS) are different.
 
Powdered and ready to drink ONS are difficult to impossible to thicken safely with starch and gum thickeners. Consequently, health care professionals prefer to reduce risks by prescribing Fresubin and Nutilis Complete pre-thickened ready-to-drink ONS.
 
They cost £2.20 each and the NHS spent £4,500,000 on them over the last year.
 
The innovation I want to introduce to your CCG's is an alternative which provide all the safety of a ready to drink ONS for the price of a powdered one. Called Slõ Milkshakes+ they are the 1st pre-thickened and powdered protein rich ONS on prescription.

Costing 84p each, they provide a saving per prescription of £ 80+ per month or £ 900+ per patient
per year. If Slõ Milkshakes+ were used during the same period they would have saved a massive
£ 2,800,000.

They also provide huge environmental savings. Slõ Milkshakes+ are presented in powder form in sachets. Not using single use plastic bottles, dramatically reduces the CO2 impact of manufacture, delivery and recycling. Our sachets can even be incinerated and used in energy recovery plan.
 
Just as importantly, Slõ Milkshakes+ are drinkable. Made with whole milk from the fridge, they taste fresh, do not taste too sweet or have a metallic aftertaste. Ultimately, that makes it easier gain compliance and maintain patient’s oral nutritional intake.
 
It’s for all these reasons they are being added to Formularies across the UK and why I want to introduce Slõ Milkshakes+ with the aim of introducing your CCG’s to
Slõ Milkshakes+.
 
There is additional useful information here: www.slodrinks.com/ons



 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Innovation and adoption / Person centred care
Benefit to NHS:
Slõ Milkshakes+ have been created to help reduce financial and environmental costs whilst improving patient outcomes - now and in the future.

Just focusing on costs - as previously stated, Slõ Milkshakes+ save £80.00+ per prescription. That may not seem like a huge amount, but the cumulative saving is huge.
 
From March 2017 to March 2018, the NHS spent £ 4,500,000 on Fresubin and Nutilis Pre-thickened ready to drink ONS. In comparison to spend on medications that is not a lot. However, spend on products for dysphagia is going to increase for two key reasons.
 
Firstly, healthcare professionals are not seeking to diagnose dysphagia. As recently as two months ago the Doctors dedicated website www.gponline.com made identifying Dysphagia a Red Flag topic.
The reason – they now recognise the impact dysphagia has on treating the primary condition.
 
If a patient is diagnosed with it every medication, drink and supplement has to be altered so it can be swallowed safely without inducing aspiration.
 
Secondly, it is a secondary symptom of 127 conditions including; Stroke, Alzheimer’s, Head and Neck Cancer and Motor Neurone Disease. These conditions present themselves typically in the elderly and dysphagia affects 10-12% of those over 50 – an increasingly large proportion of our population.   
 
We can therefore predict with certainty, if the spend on ready-to-drink Fresubin and Nutilis just remains the same the accumulative spend in 5 years will be £ 22,500,000.
 
By making Slõ Milkshakes+ a 1st line response for dysphagia now over the same period the cost of prescribing Slõ Milkshakes+ would only be £ 8,148,000, saving £ 14,352,000!

 
Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:
Slõ Milkshakes+ make a positive impact to the health and wealth of the region through saving: saving patients from the risks of aspiration pneumonia, malnutrition and readmission; saving the CCG’s and healthcare professionals from unnecessary spend on expensive ONS for this patient group.
 
 
By providing a safe and reliable method to make safer to swallow ONS, Slõ Milkshakes+ reduce the risks of patients acquiring complications.
 
Patients will find it easy to consume the prescribed number of Slõ Milkshakes+ because they can actually drink them. They know they flow at the right speed and don’t need to worry about choking or embarrassing themselves in front of others – including their spouse.
 
When made Slõ Milkshakes+ look like ordinary milkshakes. No one can tell it flows slowly. It therefore doesn’t highlight their condition; gives them a feeling of inclusion.
 
Ultimately this makes for a better patient experience and improves compliance, which in turn saves them from the risks of malnutrition and re-admission.
 
Avoiding re-admission will save all the financial and patient costs associated with it, but and more importantly Slõ Milkshakes+ keep the costs of providing adequate nutrition in the Community to a minimum, saving CCG’s and healthcare professionals unnecessary spend on finances and time.
 
The financial savings are easy to quantify. Slõ Milkshakes+ will save £ 80+ per prescription every time a prescription is written for them instead of a ready to drink ONS.
 
Your CCG’s can quantify those savings by adding up the number of Fresubin and Nutilis Complete prescribed, multiplying by 84p (the Slõ Milkshake+ cost) and comparing the two.
 
Further savings are achieved by presenting Slõ Milkshakes+ in boxes of 7. A prescription can be written for just 7 sachets – a weeks’ supply – to see if a patient likes them. If they do, a larger prescription for one month’s supply can be written.
 
It’s also important to highlight the time saved, specifically time spent on implementation and training
in Nursing Home and Care Facilities where the majority of those with dysphagia reside.
 
These facilities typically have a high turnover of staff and many do not have English as a first language. As a direct result every Slõ Milkshake+ sachet features written and pictorial instructions to make sure they are always made correctly.
 
This makes training quick, easy and efficient, allowing health care professionals to focus on other important healthcare needs.
 
Current and planned activity: 
We are in constant contact with all divisions and levels of the NHS across the UK.
 
Our primary contacts have been healthcare professionals in Acute Hospitals, their colleagues in the Community and Doctors who have prescribed Slõ Milkshakes+.

During 2018 we have been focusing establishing relationships with CCG’s and their Medicines Management Team. We have been able to make contact via some Prescribing Support Dietitians but this has been difficult and slow.
 
This is why I have contacted all other ASHN's and yourselves - with a view to meeting your CCG’s and showing them how Slõ Milkshakes+ can help them and their patients.
What is the intellectual property status of your innovation?:
Our Competitors are giant Pharmacutical Companies and therefore a patent would be difficult to impossible to defend.
As a result I have had the Slõ Brand is trademarked here and in various Counties around the world.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Mathew Done 10/08/2018 - 10:17 Publish Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Giving one drop of blood for analysis by SOMAscan informs me of my current health status, and helps my doc give me the right advice to reverse or prevent further disease development, or guide their treatment recommendations that will work first time!
Overview of Innovation:
The measurement of 5,000 blood proteins (a quarter of the human protein repertoire) is now possible on a reproducible and industrial scale in clinically-accredited central lab settings. Prior analysis of hundreds of thousands of study subjects' and patient blood samples, whose basic & physiological measurements, life style and clinical histories have been collated, has been used to create a suite of health status defining algorithms that define risk of disease event occuring over 1-5 year time horizons, rates of development, and likelihood of response to alternative intervention that are available.  Whereas rudimentary 'disease risk' insights such as Framingham cardiovascular diasease (CVD) risk scores and QRISK2 are used in public health, primary care and specialist acute care settings to augment disease prevention or guide optimal treatment choices, it is now possible to expand this range of probablistic medicine insights.  Expanding the repertoire beyond CVD to include pre-diabetes conversion to full diabetes or development of complications (amputations, kidney failure, blindness) that lead to costly or catastrophic outcomes, is a starting point.  However, diseases such as non-alcoholic fatty liver disease and steatohepatitis, which leads to liver cancer & failure is another silent killer whose development can be revealed just by applying a different status-prognosis algorithm to protein measurements derived from the same blood sample.  Chronic disease management and care accounts for ~70% of healthcare costs with diabetes alone consuming 10% of the NHS' entire budget and so these are worthy of attention for  prevention, early disease interception (at a reversible stage), or optimising existing care paths that maximise available resources to deliver disease management interventions.  Our primary focus is to prolong and improve population wellbeing such that patient treatment outcomes leads to broad adoption.  However, whereas traditional diagnoses rely heavily on clinical symptoms, SomaLogic's AI-derived algorithms consider the molecular underpinnings of disease.  Clinically-defined diseases are treated in standardised ways which doesn't always work.  Identifying patients with treatment-refractory disease could help target those into research programmes including clinical trials for novel regimens or pharmacological agents.  A secondary output of routine adoption could be creation of an accelerated trial recruitment resource to attract pharma partners.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Healthcheck, although ultimately funded by Public Health England, commissioned by City Councils and delivered through contracted CCGs/GPs, is of questionable value.  A battery of tests whose results are combined with additional clinical parameters and a consultation with a GP or practice nurse, is designed to pre-empt intervention in patients with rising risk for cardiovascular disease or identified as having 'frank' disease.  The net contribution based on opportunity savings delivered to the NHS and the cost of delivering the HealthCheck programme is close to zero.  The repertoire of diseases whose status can be tested for, could be expanded to include multiple silent diseases, as well as provision of range of physiological status-related insights that could complement the patient review process.  For example, patients at risk of developing frank diabetes could be managed more objectively and successfully.  A reduction by 1% of patients converting to full diabetes could equate to £100 million/year by their avoidance of costly complications such as stroke, amputations, kidney failure and blindness.  Avoidance of liver failure associated with liver fibrosis, could contribute further significant opportunity savings: Coupling life style (e.g. dietary education or excercise on prescription) or emerging pharmacological interventions with conveniently measured disease status insights will be required.  However, rather than creating increased burden on NHS resources, provision of clinically validated insights but could also create opportunities for third party organisations beyond the NHS in offering relevant health-maintaining or disease-reversing solutions.
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
In a county in which 29% of the population is clinically obese there is a higher risk compared to the majority of the UK population, for diabetes and also fatty liver disease-related complications.  Treatment costs for the latter alone costs the NHS (England) around £1billion/year.  Providing disease risk insights to citizens and their health practictioners, particuarly if the information is objective and made actionable, could be used to support increased health literacy, increase patient activation (motivation), and support the best choice and resource-optimal delivery of advice and clinical interventions.  Ultimately, compliance with such advice and insights will improve the healh of the local population, reduce the burden of dependancy on long-term chronic disease care, and perhaps even result in development of a health-focused preventive health solution provider market.
Current and planned activity: 
SomaLogic has submitted plans for implementation of diabetes risk and complication development predicting algorithms in the routine primary care setting in Leeds (one CCG and 3 GPs). The objective is to use the more objective patient profiling (identified through hypertention clinics) to promote deeper patient enagement measured through increased patient uptake of commissioned nutritional education programmes and/or gym by prescription.  Logistics around blood collection, processing, analysis and data delivery and presentation will be evaluated and optimised, after whcih there is scope to expand this initiative to a wider geographical region.  However, there is scope to evaluate the utility of additional disease status (risk), and prognostication algorithms within the different clinical settings and associated clinical workflows, in neighbouring geographies.
What is the intellectual property status of your innovation?:
SOMAscan is a patented proprietary protein measurement technology.  Algorithms developed using artifical intelligence to mine for associations between patient characteristics, lifestyle histories, clinical interventions and decades of clinical follow-up/outcome data (2 million years) that correlate with patterns for 5,000 protein measurements (mined from 2 billion protein data points), provides a highly defensible starting position.
Return on Investment (£ Value): 
Very low
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Anthony John Bartlett 11/07/2018 - 15:11 Publish 5 comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
This project uses art to inspire and inform, targeting geographical areas of social disadvantage where breastfeeding rates are low/ mothers may not have access to current research and may be unduly influenced by cultural barriers to breastfeeding.
Overview of Innovation:
Funded by ACE from 2017-18, the series of twenty-three photographic portraits of mothers breastfeeding by Lisa Creagh (Artist Practitioner) was animated into a film and exhibition-ready prints in January 2018. From January – May ‘Holding Time’ was shown at Fabrica Gallery, ONCA Gallery and Royal Brompton Hospital in London, in print, video and installation formats, accompanied by talks and workshops. ONCA featured a Breastfeeding Hub where comfortable seating encouraged mothers to stay longer and talk with other mothers. 
 
A dedicated website (www.the-parlour.org), was set up to broadcast interviews using Lisa Creagh’s YouTube channel. Here interviews by Lisa Creagh and Lucila Newell with participating mothers were posted as 5minute Podcasts. A Facebook promotion and postcard campaign drew visitors to the website, where a BLOG written by Sociologist Lucila Newell explored issues surrounding the cultural barriers to breastfeeding and an events page directed them to exhibitions and workshops/talks.  
 
Findings:
  1. Responses from audience at exhibitions was more mixed in gender and age than anticipated
  2. Workshops and talks were attended by more academic, medical and health researchers/practitioners than expected
  3. Online sharing of ‘Holding Time’ slideshow brought a large proportion of the audience to Podcasts 
  4. ‘The Parlour’ was not needed as a separate brand identity for the website: numbers of direct visitors were less significant than online sharing and YouTube recommendations. 
  5. The Breastfeeding Hub resulted in longer visits to exhibition
  6. Interviews/talks/workshops revealed structural barriers within health practice.
 
Figures (Jan-May 2018) 
 
Exhibitions x 10 days/ 435 visitors
Website: 1,000 users/ +67%
Talks x 2: 70 attendees
Facebook fans 303 posts/+91 fans/ +695 engagement
Instagram: +87 posts/+346 followers/ +1.4k engagement 
Twitter: 155 Tweets/+55 Followers/+25 engagements 
YouTube Analytics: 8,907 Views/ +6,710/60 Likes/+63 Subscribers
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Innovation and adoption / Person centred care
Benefit to NHS:
There is a wide disparity between the emphasis on breastfeeding in culture and the support for mothers attempting to breastfeed for the first time. There are approximately 700,000 newborn babies in the UK each year. Of these, a high proportion will be to new mothers with no experience or understanding of breastfeeding. Much funding for Health Visitor run baby groups and drop-ins throughout the country have been cut in the past two years due to budget constraints, leading to increasing social isolation of new mothers. Young mothers in particular may not have ever encountered another breastfeeding mother, given that the last generation was largely encouraged to bottle-feed. 

Holding Time is a project designed to address inequality and lack of opportunity. We know from a huge body of evidence that breastfed babies have better short and long term physical and emotional health outcomes.[1]But drop out rates in breastfeeding are still perilously high. Currently young women from disadvantaged backgrounds have breastfeeding rates of less than 29%[2]. But until cultural attitudes towards breastfeeding change, it is unlikely that this will be improved. 
 
One of the greatest challenges new mothers face is overcoming the dominant negative attitude towards breastfeeding in public[3]. The Infant Feeding Survey 2010 shows that In Brighton, breastfeeding rates are higher than the national average, but these statistics hide inequalities. 

The nature of this work is discursive,opening dialogues around breastfeeding between not only women, but also genders and generations where arguably there can be wide disparities in opinion. 

Using social media, a local postcard campaign to GPs, and a YouTube channel, the project uses the exhibition in a local community space as an opportunity to engage and invite the public to engage in multiple ways.
 
[1]Department of Health. Breastfeeding and the NHS Priorities and Planning Framework 2003-2007 (modified February 2007). London: Department of Health. www.dh.gov.uk/  
[2]https://www.jfhc.co.uk/Who_wants_to_eat_in_a_toilet_20947.aspx: “The prevalence of initiation of breast-feeding varies between neighbourhoods from 28% to 80.6%.”
[3]45% of mothers reported that they felt uncomfortable breastfeeding in front of other people, and this was most acute in public places (43%) http://www.hscic.gov.uk/catalogue/PUB08694/Infant-Feeding-Survey-2010-Consolidated-Report.pdf
Benefit to WM population:
Looking at the Public Health England Statistical findings of 2017/18 Quarter 3: the latest data on breastfeeding prevalence at 6-8 weeks after birth, areas such as Stoke on Trent, Sandwell and Nottinghamshire have particularly low rates of breastfeeding (31.8%, 37.2% and 39.5% respectively) for example but again these statistics represent take up, which would drop considerably within a couple of months. Given that the WHO has recently defended its position of the benefits of breastfeeding for at least two years, the challenge is to inspire this minority of mothers who do take up breastfeeding to continue for longer and to inspire more mothers to try, particularly young women who seem to struggle with the public face of breastfeeding. 
Current and planned activity: 
Next Stage:
 
  • Stimulate and curate conversations around breastfeeding to the public 
  • Dr Debra Bick (Expert)/Lisa Creagh to approach medical and academic researchers in the field of breastfeeding for content and collaboration
  • Podcast interviews with medical researchers, Paediatricians, midwives and heath practitioners to inform and integrate research with opinion, capitalising on the wide reach of YouTube platform. 
  • BLOG to comprise of guest posts by medical researchers focusing on issues raised by women in workshops and interviews e.g. the struggle to feed in the early stages, the establishment of lactation, post partum care, expressing, breastfeeding in public, etc
  • Tour of Holding Time to locations across the UK with low breastfeeding rates, including Breastfeeding Hubs where possible/appropriate
  • Facebook/Instagram channels to promote the exhibitions and web content above 
  • Accessibility expanded through transcripts/closed caption subtitles 
What is the intellectual property status of your innovation?:
Copyright of all images is held by Lead Artist Lisa Creagh
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Read more
Hide details
Lisa Creagh 15/06/2018 - 15:13 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Our web based visualisations of NHS datasets is disrupting the analytics market. It allows systems to understand cause and effect within their health economies and test hypothesis in real time by interacting with the data through drop down menus
Overview of Innovation:
Our vision is to give every NHS system leader in England a clear picture of the end to end journey for the populations they serve. At the same time we aim to save the NHS £millions by disrupting the market for low level analytics!
The challenge currently faced by all healthcare leaders is a lack of insight and meaningful, consistently-reported analysis regarding the position and performance of the healthcare system. This lack of insight hampers the efficacy of the strategic and operational planning process and the scope and effectiveness of monitoring and oversight.
This challenge sits in the context of masses of existing publicly available healthcare data. Data that’s time consuming for providers to prepare but underutilised due to its format, shape and local capacity and capability.
Our vision is to make VUIT.ONLINE, our information and insight portal, available across the entire NHS in England. The tools we’ve developed allow users to interrogate data across an provider, CCG, ST or ICS quickly and efficiently in a way which informs decision making and allows the impact of interventions to be validated using existing national datasets.
VUIT.ONLINE re-configures, combines and visualises NHS and other national datasets in a way that allows them to be used to understand system and provider performance and demand in context.
Our front-end combines different datasets to create insights not available from any one alone, for example combining DTOC data with hospital bed-base to understand the effective scale of the DTOC issue, or comparing RTT data with consultant workforce to contextualise waiting list trends.
By doing this we can support system leaders to gain a deep understanding of cause and effect related to key strategic issues within their ICSs and model the impact of decisions they may wish to make to address those issues.
All this is achieved with data which is consistent across all providers, layered from multiple data sources and, most importantly is instantly available, at the national, regional and place based level for comparison and analysis through an online portal.
The impact of VUIT.ONLINE is not just the creation and availability of new insights from data, but the speed at which it can be manipulated to test hypotheses.The financial viability of VUIT.ONLINE comes from its ability to deliver this with an absolute lack of in-house or procured analytical or BI resource in the form of consulting and CSU costs which currently run into many millions.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
VUIT.ONLINE re-configures, combines and visualises NHS and other national datasets in a way that allows them to be used to understand system and provider performance and demand in context.
We do this in a pre-packaged but evolving, continuously-updated front-end combining different datasets to create insights not available from any one alone, for example combining DTOC data with hospital bed-base to understand the effective scale of the DTOC issue, or comparing RTT data with consultant workforce to contextualise waiting list trends.
By doing this we can support system leaders to gain a deep understanding of cause and effect related to key strategic issues within their ICSs and model the impact of decisions they may wish to make to address those issues.
All this is achieved with data which is consistent across all providers, layered from multiple data sources and, most importantly is instantly available, at the national, regional and place based level for comparison and analysis through a scalable online portal.
The impact of VUIT.ONLINE is not just the creation and availability of new insights from data, but the speed at which it can be manipulated to test hypotheses at system level from the system’s own, current data within existing national datasets.
The financial viability of VUIT.ONLINE comes from its ability to deliver this with an absolute lack of in-house or procured analytical or BI resource. A fundamental success factor for the implementation of this innovation is a reduction in the cost of low-level analytical support to the NHS in the form of consulting and CSU costs which currently run into many millions.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
By giving system leaders the tools they require to effectively build end to end, whole system pathways and commission them outcomes will improve for the people of the West Midlands. However the way in which our innovation VUIT.Online is configured this benefit is freely available to all health economies in England
Current and planned activity: 
We are currently mid way theought the second wave of Test Bed applications where we are both an innovator and a defined test bed partner with a West Midlands CCG
What is the intellectual property status of your innovation?:
VUIT. Online and it's intellectual property is owned by its co-founders. It is built on licenced propriatry software and uses national data sets which exist in the public domain
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
VUIT. Online uses national data sets, propriatery analytcal software and globally recognised web developer frameworks (wordpress). As such it is scaleable across the entire NHS in England immediately
Measures:
Measurable outcomes:
-reduction in spend on low level analytics in the NHS in england
-reduction in patient pathway costs as health economies understand whole system costs more effectively and plan ICS's on this basis
-Improved ability to scale innovation in healthcare by giving innovators access to data which will support, clarify and stratify the way in which they develop and take their products to market
Adoption target:
We aim to make the resource available to all NHS managers in England through sharing examples of best practice around the use of VUIT.Online
Read more
Hide details
Adam Townsend 25/04/2018 - 14:31 Detailed Submission Login or Register to post comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Raiing Medical manufactures non-invasive Connected Vital Signs Monitoring for essential clinical decision support, healthcare cost savings, and better quality of care through big-data analysis and AI technology for inpatients and outpatients.
Overview of Innovation:
Currently, the majority of patients in hospital have measurements of vital signs taken manually at 2 to 4 hour intervals, which means some irregular events on the patient may go undetected for hours, this will lead to serious consequences including additional treatment, re-admittance to intensive care units, or even death. On the other hand, the lack of qualified data after patients leave the hospital also increases the difficulties for doctors to identify a patients situation at home. 
 
Raiing Medical believes wearable and mobile technology will change this situation, therefore Raiing is pleased to announce that Raiing MPCMS solution is now available. Raiing MPCMS is a continuous multi-parameter central monitoring system with smart sensor interface and transceiver, which arms to better monitor patients’ vital signs and eventually improve patients’ safety. With the support of a wearable medical sensor and unique Raiing VitalCube, nurses/care givers could receive constant ECG, TEMP, Heart Rate, Respiratory Rate, Sp02 signals from multiple inpatients and alarm for irregular readings simultaneously into a central monitoring station or hospital IT system.  
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Person centred care
Benefit to NHS:
Raiing Wearable Vital Signs Monitors will cut down dramatically on Caregivers intervention, provide essential patient data for Hospital use, Home Caregivers use and Doctors Surgeries.  The net result is an increase in patient's quality of life,  significant reduction in readmissions to hospital and considerable savings to the NHS and beyond.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
Our Wearable Monitors will allow for vital signs testing on the operating table, ICU, recovery in Hospital and uninterrupted monitoring in the home. Caregivers will pick up on fluctuations and administer assistance immediately saving readmissions to hospital or doctor intervention.
Current and planned activity: 
Our products are widely in use in China and the US.  We are now looking to introduce our products into the UK and Europe and are taking part in the Nightingale, Horizon 2000 project but have not yet had the chance to work with the UK NHS.
What is the intellectual property status of your innovation?:
Wholly OIwned by Raiing Medical Company, Beijing, China.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
John Sweeney 30/03/2018 - 12:29 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
RespiraSense demonstrated a potential for 6-12 hours earlier detection of patient deterioration when compared to the standard of care. Putting that into context, for every 30-minute delay in treating Sepsis, increases the risk of mortality by 7%.
Overview of Innovation:
RespiraSense is the world's only continuous respiratory rate monitor. Respiratory rate is the earliest and single most sensitive indicator of patient deterioration, more so than heart rate if systolic blood pressure. In fact, 26 breaths per minute are considered the earliest point of divergence between Spo2 and respiratory rate. Giving rise to 12+hours of false security is accurate RR is not measured. 

The standard of care remains the manual counting of breaths per minute, which has been shown to be biased and prone to error. With evidence showing no change in the quality of measurements for over 170 years (1846SirHutchenson) (2017Badawy). 

RespiraSense gives medical teams the advantage of being able to intervene early, thus reducing time to intervention and improving outcomes. Outcomes such as Average Lenght of Stay, Average Unit Cost of Care, and Patient Safety targets can be achieved. 

RespiraSense is a simple, wireless, and discrete wearable monitor, placed on at admission and worn/measuring continuously for upto 7 days. Each patient recieves a new sensor and a reusable electronic device or Lobe. See how the system works @ 
https://www.youtube.com/watch?v=u6KB1hBPQbM​ 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Each year, there are approximately 500,000 admissions of Sepsis and Pneumonia with an average unit cost of £4,600 per admission. These two conditions are increasing in incidence and oftentimes lead to an escalation of care due to the risk of undetected deterioration. It is shown that a 5% reduction in the escalation of care of these two pathways alone, through the use of continuous Respiratory Rate monitoring triggering decreased time to interventions (Fluids, Oxygen, Antibiotics, Steroids), can reduce the average unit cost by £300 and the average length of stay by 0.5 days. This translates into a total Net cash saving of £115m and 250K bed days. Popular opinion suggests that as high as 20% reduction is achievable - Evidence pending. 

Each event prevented, having an average cost of £25,000, will pay for a whole year's supply of sensors for one year. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
West Midlands Trusts are driving the awareness of Sepsis through their ambulance services, patient awareness campaigns, and in-hospital initiatives. With 44,000 lives lost each year attributed to Sepsis, it is important to Prevent, Diagnosis Early, and Effectively Treat the condition. RespiraSense focused on the area of Diagnosis Early. Research suggests that NEWS2 is a more sensitive indicator of deterioration due to Sepsis than QSOFA. Both of which have Respiratory Rate as a key parameter to measure. There is clearly value in monitoring this essential vital sign accurately, and clear additional benefit to having it monitored continuously. RespiraSense achieves both with low impact of False alarm due to its innovative design, boasting advanced motion-tolerance. 
Current and planned activity: 
PMD Solutions is working with Nursing Times to launch an educational campaign on the clinical science and importance of respiratory rate monitoring in acute care clinical practice. 

In addition, PMD Solutions is looking for Respiratory and Emergency teams to partner with and create a culture of Peer Leadership in the development of best practice for respiratory rate monitoring. 
What is the intellectual property status of your innovation?:
RespiraSense is positioned to be the new industry standard in respiratory rate monitoring. It is patented in Europe, United States, China, Hong Kong, and Japan. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Myles Murray 02/03/2018 - 19:46 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Feedback Centre enables organisations to collect feedback from any stakeholder. This information is presented via a visual dashboard called Informatics, allowing health organisations to spot trends & issues and act on them or plan improvements.
Overview of Innovation:
Feedback Centre has been developed in collaboration with and for the NHS and Health & Social Care organisations.

Feedback Centre brings together public feedback, survey results and complaints, all of which can be shared directly with stakeholders/service providers. This allows data from multiple sources to be joined-up, stored in one place and shared organisation-wide. 

Feedback can be collected online, including by tablet, mobile, Facebook and via widget, as well as via SMS and kiosk. This offers a great choice for patient engagement and allows patient experience teams to gain information from a broad cross-section of society, as different social, economic and clinical groups often communicate via very different means. The system also allows offline and archived feedback collected from other sources to be imported into Feedback Centre.
                                                                                                           
Feedback Centre also includes a screen-reading and translation feature with the aim of preventing the exclusion of those with visual impairments or poor literacy skills from engaging with providers.
 
Health & Service providers are able to respond publically to feedback, shortening response times to public concerns and reducing the volume of incidents that escalate to formal complaints.
 
Our business intelligence dashboard, Informatics, presents the fastest way possible for Health organisations/Trusts to access data, understand trends and create reports. It will also provide clients with the ability to utilise their own taxonomy, categorising the data in any format required. This allows for benchmarking of providers, services and departments, as well as identifying areas for potential improvement.

Utilising sentiment analysis, Feedback Centre will determine the emotional tone behind a series of words. This can be used to gain an understanding of the attitudes, opinions and emotions expressed within a review or complaint. Thus they can be weighted for seriousness and therefore flag providers to take note and take instant action
 
To ensure confidentiality the system is hosted by EKKO securely to NHS Trust information governance standards with monthly updates provided to the platform. 
 
To see Feedback Centre in action, take a look at the following video featuring Healthwatch and NHS England: http://www.EKKOmedia.com/healthwatch-video/
 
Benefits:
  • Branded system for any organisation
  • All information available in one place
  • Secure, ISO27001 Hosted Surveys and GDPR ready
  • Less risk, all information is shared directly with client only
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
A single database for ALL experience data: The key benefit to the NHS is the storage of all user & staff experience data into a single database, which can be, used organisation-wide by an unlimited number of users with different levels of access. Hence this aggregation of data provides:

A facility removes the risk of inefficiencies due to having multiple, unconnected silos of disparate information, training is provided every step of the way by EKKO.
  • Peace of mind for GDPR compliance and ISO27001 hosting, utilising world leading hosting architecture Amazon Web Services.
  • An ability to create a snapshot or larger historic overviews of analysed data on single aspects or wider views of experiential data and trust feedback    
  • Services and providers to be benchmarked, allowing the identification of top performers or highlighting underperforming providers or departments. Alternatively it can show issues where quality or care does not match KPI’s, indicating a need for investigation or a comparison to be made. 
     
  • Creation of specific taxonomies; Trusts can categorise their data to ensure that the words and meanings meet that of their patients within in different clinical, social and ethical groups, so as to remove barriers whilst ensuring data integrity and meaning is maintained when analysed and reported on.
     
  • Through the multi-channel approach it allows Inclusivity and increased response rates while maintain data cohesion. Feedback Centre can be used to engage with a broader cross-section of society, resulting in higher response rates for surveys. e.g. young people and those within the working population are often unable to attend Patient Participation Group (PPG) meetings, meaning they are often under or not represented in survey results. Allowing those groups to complete a survey via a smartphone or Facebook application which increases the likelihood of gaining a more representative sample within the Feedback Centre database.
     
  • Cost savings on external surveys suppliers - The system can be used to administer the Friends and Family Test, as well as any other mandatory or ad-hoc NHS surveys, including staff surveys. Using the system for surveys removes the need for external partners to conduct surveys, hence a significant saving. (The system has no limit on users or the creation of custom surveys, thus no additional costs per survey). Whilst also ensuring all survey data is held by the Trust and in one place for future reference and analysis.

Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
How do the public see their responses or outcomes/results of feedback they give?



Give YOUR Patients & the Public a voice for feedback and complaints
We provide the WM population with a place to share feedback safely about services that they use. All health and care providers can feature on the system. Feedback is displayed publicly after moderation, allowing anyone to compare and benchmark providers based on real experiences.
 
The system is multi-channel, inclusive and easy to use
A significant proportion of the NHS’s engagement is done via Patient Participation Groups (PPGs). PPGs are not always representative re: age, race & gender, as well as numerous other demographic factors. This is due to people being unable to attend PPG meetings due to being at work, school or condition they are being treated for. By offering a multi-channel solution, members of the public are able to leave feedback online, increasing the likelihood of gaining direct feedback and insights from those groups. A text-reader service can be added to the site to enable those with visual impairments and speakers of other languages to give feedback.
 
Our technology can be used to broaden ways users engage in feedback. Thus we wish to work with health providers to explore & develop such processes & systems.
 
Provider responses
Service providers are able to respond to reviews publically or privately, addressing concerns before they escalate into serious issues or formal complaints. This demonstrates to the public that they are being listened to, inspiring confidence in services & can be used to intervene in more serious alerts & complaints.

Branded, secure portal
The system is branded to health clients’ guidelines to ensure uses have confidence with whom they are engaging with and responding too. Security and hosting is to NHS Trust IG standards with Amazon Web Services. All data is hosted in the UK and load-balanced, ensuring availability of systems at all times.
 
Using a secure, online portal offers a greater level of security than collecting data offline/paper, as well as providing significant cost savings. Currently, most patient experience data is collected and stored offline in a multiple, which has implications in terms of the GDPR regulations that come into effect in May 2018.
 
Monitoring & reporting on changes
Centralisation of cohesive data provides the ability to compare and contrast between service, timeframes and as a way of gauging and monitoring any changes that are made.
 
Current and planned activity: 
Current
We work with NHS trusts, CCGs, Healthwatch network & local. System is showcased at UK events with major update due -Feedback Centre 2.0. Long term aims are to roll-out across NHS, Care & Housing sectors

Regional Scalability
Explore West Mids roll out as it has not yet been scaled across an entire NHS region previously. NHS E & SWAHSN funded regional roll-out across 7 Healthwatch network organisations
 
Individual CCG, Trusts, STP, Healthwatch & GP federations uses are possible. Regional or large scale adoption could provide individual as well as wider insights to services & their performance & satisfaction levels.
 
Wish to hear from
Organisations wanting Feedback Centre demo: - GP, CCG, Trust or other health/social care provider
 
Evaluation & Validation of system benefits, monitoring delivery, ensuring + patient experience
 
Product Development – expand ways patients can engage & provide feedback
 
What is the intellectual property status of your innovation?:
Feedback Centre is copyright protected, having been created by EKKO. Data held within the system is the IP of the client, with EKKO performing the role of data processor.

Regulatory Approvals:
EKKO hold the following approvals: 

Cyber Essentials: EKKO have completed Cyber Essentials, a Government-backed, industry-supported scheme to help organisations protect themselves against the most common threats found on the internet.

GDPR Foundation Certification – EKKO have completed this certification with the aim of helping our clients prepare for the new regulation requirements.

Data Protection Public Register: ZA310893
 
IG Toolkit – EKKO are currently working towards the IG Toolkit and aim to have this completed by April 2018. 
 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
Ian Hughes 15/02/2018 - 17:28 Publish 1 comment
5.5
2
Votes
-99999
Innovation 'Elevator Pitch':
Consultant Connect enables a GP to dial a single number to immediately reach an appropriate specialist.  Immediate Advice and Guidance is better for patients, clinicians & NHS. It is currently used in Elective, Urgent & Mental Health care settings.
Overview of Innovation:
Consultant Connect www.consultantconnect.org.uk is a simple CCG funded telecoms system that provides GPs with immediate access to telephone-based specialty mental health advice and guidance. By talking to a specialist, often whilst the patient is still in the surgery, the GP is better able to provide the right care first time to the patient, often avoiding an unnecessary referral or admission.  The specialist is based within a nearby NHS Trust Hospital.
 
GP calls connect directly, via a standard rate number, to teams of local specialists via their mobile phones with each specialist getting c 20 seconds to answer a call before it automatically forwards on to the next specialist. By connecting to teams of specialists, rather than to individuals, the connection rates are high.  The order in which specialists receive calls is based on a Rota of specialist availability that has been provided by the team. This rota can be either managed by us or by the team itself through an online portal.  The team of specialists are based in the local NHS Trusts.
 
Once connected, calls are recorded as highly encrypted, information-governed digital files which provide a medico-legal record which is available to the relevant GP practice and specialist team.  At the end of the call GPs are asked to stay on the line for a few seconds to rank the outcome – this gives the CCG a broad view as to the effectiveness of the system and their investment in it. Specialists are also asked to rank the outcome via text message as a back-up.
 
This service is in operation nationally across many specialties in physical and mental health.

In what instances should/can Consultant Connect be used?
The way in which this system is used is ultimately determined by the CCGs, Trust/Specialists and GP practices collectively, but it is generally accepted that calls will be made for patient-specific advice.
 
Within mental health we can connect GPs to the most appropriate mental health clinical professional (e.g. Psychiatrist, Psychologist, Cognitive Behavioural Therapist) to discuss issues such as:
  • Whether a referral is needed
  • Medication management/prescribing questions
  • Access to crisis support
We offer our service to best meet local needs between service users, GPs and Mental Health Trusts. 
 
We can tailor by service, specialty or pathway.
The speed of connection is such that the GP’s can (at their discretion) call whilst a patient is still with them.

Consultant Connect Service
https://www.youtube.com/watch?v=QWmNUubMCAE
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Why Trusts and CCGs work with us
  • Better patient experience – speeds up the care pathway, avoidance of unnecessary visits and contact with secondary care services, reductions in follow-up visits to GP Practices
  • Better GP experience – more patient episodes conclude with no follow-up work, case based learning, reconnecting with specialists
  • Better specialist experience – reduction in inappropriate referrals to secondary care services, reduction in the number of written requests for advice that require responses, reconnecting with GPs
  • Better for the mental health trust and CCG – full tracking of Advice & Guidance activity, greater ‘whole system’ efficiency, with savings available to support other hospital and community initiatives

How we perform
  • In Physical Health, across all elective care specialties, 66% of calls to Consultant Connect result in the patient avoiding a trip to hospital (referral or admission)
     
  • In Physical Health, across all of urgent care specialties, 27% of calls avoid a hospital trip that day (attendance or admission) and a further 36% of from A&E
     
  • In Mental Health, 39% of calls to our Mental Health Advice & Guidance line avoided a referral
 
What a Consultant Connect call has meant to …
… GPs
“The call enabled me to deal with some abnormal results in an efficient manner – which tests to request and what to do with the results. Saved a referral.”

… Consultants
“I took a call regarding a patient with syncope and ataxia. I avoided an unnecessary admission and got the lady seen urgently in an outpatient clinic.”

… Commissioners
“Consultant Connect is our only QIPP scheme that is over delivering against its YTD QIPP target. I’m genuinely struggling to know how to deal with all this positivity. It’s very unusual in my line of work. Great news.”
 
Testimonials:
https://www.youtube.com/watch?v=vEu7QDT4PzI
 
Initial Review Rating
4.80 (2 ratings)
Benefit to WM population:
Nearly 2,000 patients were spared an avoidable visit to hospital in the West Midlands by GPs who used Consultant Connect to contact specialists for immediate advice.
 
Doctors in the West Midlands turned to Consultant Connect, which allows them to speak to a specialist, often with the patient still in the room and can save them waiting days for a response or being sent to hospital for further checks.
 
Around 1,850 patients were spared going to Sandwell Hospital as well as Heartland and Good Hope Hospitals in Birmingham.
 
The service covers cardiology, diabetes and endocrinology, gastroenterology, gynaecology, general surgery, haematology, paediatrics, renal medicine, urology and respiratory medicine.
 
Since the phone line launched, GPs from 100 surgeries across Walsall, Sandwell and Solihull have made nearly 2,500 calls to specialists to get expert advice on the best care for their patients.
 
Consultant Connect estimates that West Midlands GPs and consultants have saved the NHS £570,000 by ensuring patients get the right treatment from the beginning.
 
When local GPs used Consultant Connect, around 50 per cent of their patients avoided the inconvenience of a trip to hospital.
 
Ref: Pharmacy Choice, 9 June, 2017
https://www.pharmacychoice.com/news/article.cfm?Article_ID=1832970
In one West Midlands CCG, the number of outpatient referrals dropped by 6 per cent over a three-month period.   This was Solihull CCG into HEFT (Heart of England Foundation Trust). 
https://www.consultantconnect.org.uk/breaking-news-ccg-establishes-consultant-connect-responsible-for-6-dip-in-referrals

We are currently working with the following CCGs in the West Midlands AHSN area:
 
Solihull CCG, Coventry and Rugby CCG, South Warwickshire CCG, North Warwickshire CCG, Worcestershire (South Worcestershire CCG, Redditch and Bromsgrove CCG and Wyre Forest CCG).  We are also working with the GP Federation Modality Partners in Sandwell.
 
We are working with the following Trusts:
  • HEFT - Heart of England NHS FT
  • SWFT - South Warwickshire NHS FT
  • UHCW - University Hospitals Coventry and Warwickshire NHS Trust
  • WAHT - Worcester Acute Hospitals NHS Trust
  • Sandwell and West Birmingham Hospitals NHS Trust - SWBH
  • George Eliot Hospital (GEH)
Current and planned activity: 
Current activity:
We are delivering Consultant Connect with over 45 CCGs across the UK, covering more than 12.8 million patients and over 1,700 GP practices.  To date we have handled 98,000 calls.

Planned/Required activity:
We would like to further roll out Consultant Connect to willing GPs and Trusts.  We would also appreciate any assistance in undertaking a formal return on investment review of our service to show very clear and robust data that we save money, and quickly.
 
What is the intellectual property status of your innovation?:
Consultant Connect Ltd own the telecoms system software and BI data reporting.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Jenny Welling-Palmer 15/02/2018 - 13:38 Publish 1 comment
6
1
Votes
-99999
Innovation 'Elevator Pitch':
NATROX® Oxygen Wound Therapy is a medical device designed to heal complex non-healing wounds to improve healing outcomes and quality of life, optimise clinical and economic resources, and reduce diabetic foot related amputation rates.
Overview of Innovation:
NATROX® Oxygen Wound Therapy is a portable, lightweight and easy to use patient-friendly device, designed to topically deliver continuous pure humidified oxygen to the wound bed. The device was developed in order to help improve healing outcomes in wounds which traditionally remain static due to wound hypoxia (oxygen starvation), a common symptom of diabetic and vascular issues.

The NATROX® system is comprised of an Oxygen Generator, 2 rechargeable batteries and a single-use disposable Oxygen Delivery System.  The therapy is designed to be used 24/7 and as an adjunct to standard of care, such as absorbent wound dressings, with an average therapy length of 12 weeks. The product is supported by a growing portfolio of clinical evidence, including RCT-level data, which has demonstrated a significant increase in the healing rates of complex and non-healing wounds, compared to standard of care alone (90% healing with NATROX®  vs 30% for standard of care).
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Innovation and adoption / Person centred care
Benefit to NHS:
It has been shown that over £5.3bn is spent by the NHS each year on the management of 2.2m wounds. The management of non-healing wounds accounts for a significant amount of NHS resources (approx. £3.1bn per year) and is increasing due to an ageing population and higher rates of diabetes and diabetic foot ulceration.  NATROX® therapy is designed to positively impact healing rates and thereby optimise both clinical and economic resources used on non-healing wounds, in turn helping clinicians and financial decision-makers to access and treat a greater number of patients.

Furthermore, it is well documented that patient quality of life is negatively impacted by having a wound, and especially a non-healing wound, with increases in social isolation and depression across this patient population. NATROX® therapy focuses on healing wounds which are unable to heal with standard treatments alone, as these treatments are unable to address the underlying causes of non-healing wounds, such as oxygen starvation (hypoxia). The therapy system therefore focuses on providing pure humidified oxygen to hypoxic wounds, whilst being comfortable, quiet, lightweight and easy-to-use for the patient, allowing normal mobility without any negative impact from the device.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Increases in diabetes rates across the UK has in turn led to an increase in prevalence rates for diabetic foot disease and associated ulcers.  Furthermore, latest health economic evidence (e.g. Guest et al 2015 & 2017) has shown that non-healing wounds account for approximnately 57% of wounds at any time are deemed non-healing, which has a direct impact clinically, financially and to the patient experience.  Both minor and major amputation rates are increasing as a result due to the complexity of many diabetic foot ulcers, which has a significant impact on the health and wellbeing of these patients, with increased patient mortality following amputations of around 50% within 2 years.

Like many areas, the West Midlands is experiencing increased amputation rates, as a result of rising diabetes and diabetic foot ulcer prevalence.  This has a significant impact on the local health economy in the West Midlands area, especially in higher population bases such as city areas and surrounds.  Therefore, the adoption of NATROX® therapy across the West Midlands area could have a significant effect on helping to reduce non-healing levels within the diabetic foot ulcer population, and therefore positively impact the well documented clinical and economic cost that the burden of non-healing wounds brings with it.  

A resulting increased resource utilisation would allow a wider focus on the growing population of diabetic foot ulcer patients, improving clinical and economic output across local vascular, podiatry and wound management services.   
Current and planned activity: 
Inotec AMD is currently engaged with a variety of clinicians and decision-makers across the UK.  There are a number of local product evaluations active or soon to start, which will aim to demonstrate product afficacy in order to facilitate adoption of the technology locally and nationally.  in addition, a large NHS funded UK-based RCT is underway, which is due to report later in 2018.

Furthermore, the product is being reviewed both clinically and evidentially on a national level in both Scotland and Wales, where we are about to start a national clinical evaluation in Wales across both Welsh Podiatry and Tissue Viability networks, whilst in Scotland NATROX® therapy is being formally assessed by Health Improvement Scotland and the Scottish Health Technologies Group, in order to gain an official recommendation. 
What is the intellectual property status of your innovation?:
The intellectual property surrounding NATROX® therapy is owned by Inotec AMD Ltd.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
NATROX® Oxygen Wound Therapy is not yet adopted at scale within the UK, but is undergoing product evaluations with a view to contract listings and wider adoption.  A programme of marketing and events is planned to support the wider awareness and adoption of the technology.
Measures:
Further clinical efficacy demonstrated through local and national product evaluations, health efficiency data supported by the NATROX® Health Efficiency Model utilising local clinical data and outcomes, patient quality of life data from local and national product evaluations, and usability info from clinical usage.
Adoption target:
Availability of NATROX® Oxygen Wound Therapy on podiatry, vascular and tissue viability product formularies and listings in hospitals across WM region, for use on all clinically relevant non-healing and complex wounds. 
Read more
Hide details
Nick Howard 12/02/2018 - 18:23 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Digital Transfer bag for essential clinical patient information such as medical, falls and frailty information, diet/nutrition/hydration etc. To improve patient safety and provide important information to HCP's for patients conveyed.
Overview of Innovation:
Creation of a Digital Transfer bag for essential clinical patient information such as medical information, falls and frailty information, diet/nutrition/hydration etc. To improve patient safety and provide important information to Health Care Professionals for patients conveyed to Emergency Departments, hospital appointments or occupational therapy services. The app can also incorporate additional elements that will help to tailor their care such as an electronic falls risk assessment (eFRAT), simple initial questionnaires i.e. recent coughs and colds, general health, mental health, stability checks. Integration of Point of Care testing such as UTI testing for symptomatic patients. Results can be emailed to GP/ night nursing services for treatment prescription if required. Quick identification and treatment can improve patient experience and reduce falls risk associated with UTIs.
Stage of Development:
Ideas stage - Early concept and ideas stage
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Frail older people living in care homes are amongst the most vulnerable in our society.  Often simple referrals for outpatient clinics are aborted due to lack of sufficient information available and availability of knowledgable staff to accompany the patient.  Calls to paramedics result in conveyances for the same reason.
Within a care home when someone is conveyed to hospital they must be accompanied by a member of staff, this could be any one who is available, and they may not have a lot, if any, medical knowledge or knowledge of the persons previous health. Using an app would mean anyone would be able to travel to hospital with the patient as they would have all the information they would require on admission.
Currently personal and clinical information and standardised paperwork is being sent along with the patient in the ambulance. This opens up the possibility of sensitive data being lost, or not passed on to the care team who need it. The app would store encrypted data within the N3 network. Could utilise DM+D (Dictionary of medicines and devices) to reduce input error for medication information.
Ideally this could be operated in a phased approach with basic services initially and others added on in a second phase.
Care homes provide a vital service within the national health and care system, however due to insurance requirements many have become increasingly risk-adverse, insisting that the slightest stumble, confusion or change in a patient be medically reviewed.  With falls alone this results in calls to ambulance services that often result in unnecessary conveyance because the information is not routinely available.  Clinical, paramedic and patient time is wasted due to repeated appointments and attends due to insufficient information available at the point of incident.
 
Benefit to WM population:
Improved, faster treatment for illnesses, remote monitoring by qualified staff reducing need for appointments and long waiting times.  Nominated professionals and individuals can hold virtual consultations using shared information.
Current and planned activity: 
Early engagement and development has been discussed as part of an existing AHSN project in the East Midlands, but this area of work is not part of that project, and has been identified as an area of innovation and improvement.
A digital platform is already available and can quickly be tailored to deliver many of the requirements here, and this constitutes the current Phase of the work.
Next steps would be to engage with selected homes of both residential and nursing home categories and varying sizes to test performance, with the aim to roll out within a twelve month period.  
The following developments would be to work with other innovation partners to integrate with others digital technology platforms to support care homes in managing their patients, it would also be further developed to enable roll out in assisted living, sheltered housing and residential properties.
What is the intellectual property status of your innovation?:
This product is in development, and this is the first time we have shared it as we are now at the point of needing further advice and assistance.  WMAHSN have been approached to support us on protecting the IPR for this innovation.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
3
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Read more
Hide details
Andrea Baker 02/02/2018 - 19:13 Sign Posted 3 comments
0
0
Votes

Innovation 'Elevator Pitch':
Simple visual tools that enable people who cannot communicate to convey the location and nature of their pain or discomfort. They can then be given appropriate support and treatment.
Overview of Innovation:
Many people suffering pain and discomfort cannot tell anyone about their distress. They may have a permanent or temporary communication difficulty, or they cannot speak English. Because of this, their pain and discomfort may be ignored.
 
Show Me Where is suite of simple visual tools that enable adults and children to convey the location and nature of their pain or discomfort. They can then be given appropriate support and treatment.
 
Show Me Where was created by Irene Hammond, a school nurse from the Hollies Special School, Cardiff for children with autism and speech disabilities. These children were unable to communicate pain and were impossible to examine because of anxiety or sensory issues. 
 
Since being introduced Show Me Where has been recognised as a valuable resource for a much wider range of people in a variety of settings including clinical, education and domestic.
 
Show Me Where is available in printed and digital app versions (via Apple and Google Play App Stores) for both children and adults. The apps also offer a range of languages to facilitate communication with non-English speakers. 
  • Arabic
  • Bengali
  • Polish
  • Somali
  • Urdu
  • Welsh
Show Me Where can be used with a wide range of people and in any setting:
  • Stroke   
  • Autism (ASD)
  • Dementia  
  • Disabilities e.g. CP, MS
  • Deafness and hearing problems
  • Intubated or tracheostomy
  • Trauma or anxiety
  • Non English-speakers
"We use Show Me Where as part of the Pain Assessment and Management Toolkit for Patients with Communication Difficulties in all clinical areas. We endorse its value in clinical practice." Sue Mogford, Lead Nurse, Pain Team, Cardiff and Vale UHB

The tools are very simple to use. Affected people are presented with a version of Show Me Where and asked if they are in pain. If ‘yes’ is indicated they are shown a list of body images to select from. Very quickly an accurate assessment can be made of the location and nature of pain and discomfort. Presenting the tool on a regular basis reduces stress and anxiety and ensures the early detection of pain with vulnerable people.
 
In a clinical environment it is helpful for family, friends and nursing assistants to triage individuals and therefore support a more rapid and effective examination by healthcare professionals. It also enables clinicians to inform the patient and gain consent for medical examination and interventions.

"This app is brilliant!" Sunshine Haskell BA Hons, PGCE Teacher, The Hollies Special School
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Many people suffering pain and discomfort are unable to tell anyone about their distress. They may have a permanent or temporary communication difficulty, or they cannot speak English. Because of this their pain and discomfort may be ignored. Show Me Where makes diagnosis and treatment more effective and efficient for health and social care professionals. It aslo improves the quality of life for individuals living with the pain and discomfort. Accessibility and parity are both improved.
Initial Review Rating
3.00 (2 ratings)
Benefit to WM population:
Many people suffering pain and discomfort are unable to tell anyone about their distress. They may have a permanent or temporary communication difficulty, or they cannot speak English. Because of this their pain and discomfort may be ignored. Show Me Where not only improves the detection, treatment and management of pain it makes diagnosis and treatment more effective and efficient.
Current and planned activity: 
Show Me Where has been available for some time via Cardiff and Vale University Health Board. They have entered a partnership with Focus Games Ltd to make the tools more widely available by promoting the tools more effectively. Show Me Where is officially endorsed by the following organisations
  • University Hospital of Wales (C&VUHB)
  • Llandough Hospital (C&VUHB)
  • St David's Children's Centre (C&VUHB)
  • Ty Hafan, Children's Hospice
  • Special Needs Schools in Wales
  • Welsh Ambulance Service Trust (WAST)
What is the intellectual property status of your innovation?:
IP is owned by Cardiff and Vale University Health Board
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Regional Scalability:
Being widely used in hospitals and special schools in Wales.
Measures:
Improve the recognition of pain and its management among people with communication difficultis. Especially vulnerable groups.
Adoption target:
Ideally every organisation or individual that deals with people who have communication difficulties would use Show Me Where. There is no minimum viability level.
Read more
Hide details
Andy Yeoman 29/01/2018 - 08:52 Detailed Submission Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Our award winning, low cost, high impact Patient Care Packs have been developed in collaboration with over 50 NHS Trusts to address the most common needs of patients and free up front-line staff time to spend on nursing and compassionate care.
Overview of Innovation:
Patients are often admitted to hospital at short notice. This means that some come ill equipped for their stay without event basic hygiene essentials, at what is often a confusing and difficult time.
 
Evidence indicates that nurses spend more than 5 minutes per patient obtaining essential items, or people survive without, having a negative impact on their well-being and impeding nursing ability.
 
Patient Care Packs (PCP’s) include essential items (such as toothbrush, toothpaste, grip socks, ear plugs and eye mask) everything a patient needs for their own personal hygiene, protecting their dignity and enhancing the feeling of comfort.


 
Our in-house assembly offers the flexibility to tailor packs to your specific requirements and include maps, questionnaires and information about staff and facilities, which will free up staff time to spend on nursing and compassionate care.
 
University of Leicester research proves that patient care packs save nurses more than 40 minutes per shift (1:8 patient ratio) enabling more effective nursing and saving the cash strapped NHS £1,705 per band 4 nurse. Read a two page summary of the research study or download the full report here.
 
Key findings from the research study conducted by the University of Leicester include:
 
94% of patients felt that PCP’s ensured they felt cared for during their hospital stay.
 
84% of nursing staff felt that PCP’s saved them more than 5 minutes per patient, releasing at least 40 minutes per shift, improving job satisfaction for 9 out of 10 nurses.
 
93% of nurses felt that PCP’s promoted positive interactions with patients.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Innovation and adoption / Person centred care
Benefit to NHS:
The HSCIC Indicator Portal Website show emergency hospital admissions (all conditions – data for 2014/15) in England as 5,131,589. Source: https://indicators.hscic.gov.uk/webview/
 
Hospitals have also experienced increases in the number of emergency admissions of older patients, by 18% between 2010-11 & 2014-15. Source: http://bit.ly/2tuy9we
 
The use of Patient Care Packs (PCP’s) provides tangible benefits for NHS Trusts through cost savings in procurement compared to competitor products, releasing nursing staff time and reduced demand on storage space.
 
PCP’s are essential toiletries available in one pre-packaged, easy-to-store, easy-grab pack. Receiving a pack improves the admission and care experience for even the most isolated and vulnerable patients.
 
PCP’s were piloted back in 2007 at the request of Leicester Hospital’s Chaplaincy, who were concerned that patients were being admitted with no basic care items and didn’t have family or friends nearby who could bring them essential items in an emergency situation – people like the elderly or homeless.  Staff may have had a few supplies, but these always ran out very quickly and then considerable nursing time was being expended in trying to obtain essential items for patients. A 3 year investment from the Department of Health in 2012 launched Personal Care Packs as a national social enterprise scheme.
 
PCP’s are viewed positively by nursing staff due to their role in conveniently and efficiently enhancing the quality of care to patients.
 
Patients also view PCP’s positively, perceiving that they improve their comfort, dignity and promote a feeling that they are being cared for.

Initial Review Rating
3.93 (3 ratings)
Benefit to WM population:
The HSCIC Indicator Portal Website show emergency hospital admissions (all conditions – data for 2014/15) in the West Midlands as 590,475. Source: https://indicators.hscic.gov.uk/webview/
 
The use of Patient Care Packs (PCP’s) provides tangible benefits for NHS Trusts through cost savings in procurement compared to competitor products, releasing nursing staff time and reduced demand on storage space.
 
PCP’s are sold to NHS Trusts through a social enterprise with the profits used to support the charity Giving World. These packs are distributed by nursing staff to the patients at the point of admission.
 
The attached research study conducted by the University of Leicester reported Nursing staff that use PCP’s found them beneficial in discharging their duties, enhancing the care they provide as well as leading to an increase in their job satisfaction through better patient-nursing staff relations. The use of PCP’s enables nurses to save time in performing their duties, relieving them of an administrative and logistical burden.
 
The report indicates that this time saving can be used to off-set the overall cost of the pack. The research has also provided an evaluation of the financial value of PCP’s when compared to alternative care packs. The compact nature of PCP’s also provides additional benefits in the space required to store the items.

The packs are proven to save 40 minutes per shift (assuming 8 patients cared for per shift), equating to between £8.58-£14.77 for band 4-7 staff.

Cost of 8 standard packs per shift (1 per patient) is £7.60, resulting in a saving of between £0.98-£7.17

Current and planned activity: 
We are the supplier of choice to over 50 Hospitals across the UK for customised patient care packs, including Guy’s & St Thomas’ Hospital’s Award-Winning Patient Pack. 100% of profits go to helping people living in poverty right here in the UK.
 
We would like WMAHSN to help to identify opportunities to offer Patient Care Packs to NHS Trusts in the region, enhancing the care they provide to patients by protecting their dignity and providing a feeling of comfort, as well as helping to increase the job satisfaction of nursing staff through better patient-nursing relations.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Sujata Sabharwal 06/11/2017 - 10:35 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
The Hydrant is a novel and effective solution of proviiding fluids to those patients with poor mobility or requiring flat-bed rest. it consists of a bottle and drinking tube that can be postioned to allow the patient to independently consume fluids.
Overview of Innovation:
 Within the NHS dehydration remains a significant problem with recent reports suggesting it may affect as many as one in seven hospital patients and cost the NHS £1 billion a year. The majority of hydration in secondary care, is reliant on patients’ independent consumption of fluids.One way to improve hydration amongst these groups of patients is to increase accessibility of fluids using drinking aids. These aids encompass a broad range of products from insulated mugs that maintain drinks at the appropriate temperature to more complex devices designed for patients who find it difficult to drink from standard vessels. it consists of a bottle with an adjustable, self-supporting drinking tube with a bite valve that allows patients to draw fluid from the device. The device has won design awards and offers a sensible solution to providing fluids for those patients with poor mobility or physical capacity, or otherwise confined to flat-bed rest. The bottle has been trialled on the Neurosurgery ward at UHB and was greeted favourably by staff and those patients offered it. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Innovation and adoption / Person centred care
Benefit to NHS:
Within the NHS dehydration remains a significant problem with recent reports suggesting it may affect as many as one in seven hospital patients and cost the NHS £1 billion a year (Good, Richard 2014) with elderly patients particularly susceptible due to their diminished thirst sensation and changes in kidney function (Hooper 2014).  The majority of hydration in secondary care is reliant on patients’ independent consumption of fluids.  The act of drinking appears a straightforward response to a physiological need yet it is in fact a complex behaviour determined by a variety of factors and their interactions (Koster 2009) including physical, psychological, and environmental influences (Kenney 2001). In the ward environment patients rely on the support of health care providers and yet staff frequently report a number of barriers to performing hydration care with insufficient time as a key barrier amongst them (Simmons 2001; Mentes, chang 2006). This can leave patients with limited movement, cognitive ability or higher clinical dependency particularly vulnerable to dehydration. One way to reduce this risk is to increase accessibility of fluids using drinking aids such as the Hydrant. 
Initial Review Rating
4.00 (2 ratings)
Benefit to WM population:
As above
Current and planned activity: 
The primary issue with its upatke within UHBFT was the availability of the device. Staff on wards where patients would benefit from its use were unable to procure the device.
We propose that WMAHSN facilitate a series of meetings with key staff involved in procurement at the hospital to improve the supply and availability of the bottle.
Once the bottle is more freely available we propose to raise awareness of its availability with staff on the relevant wards.
 
What is the intellectual property status of your innovation?:
Licensed product of Hydrate for Health Ltd,
http://www.hydrateforhealth.co.uk/our-products/the-hydrant/
 
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Ian Litchfield 03/11/2017 - 12:18 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Children are at risk of serious harm or even death because adults are mixing alcohol consumption with caring and parental responsibilitie. This campaign poses the question - "when parents drink, who's in charge?'
Overview of Innovation:
Parents from all backgrounds are putting their children at risk when they drink alcohol at home.

The 'Who's In Charge?' campaign from Birmingham Community Healthcare NHS Trust depicts real life child harm scenarios and asks – ‘when you drink, who’s in charge?’

The campaign was conceived in response to concerns that growing numbers of babies and children are at risk of serious harm because of the way their parents consume alcohol at home.

Safeguarding professionals warn that children are being placed in danger and even losing their lives because adults who in many cases do not consider themselves excessive drinkers are not exercising normal levels of care and attention while drinking or recovering from the after-effects of over-indulgence in alcohol.

And they warn of a ‘double jeopardy’ effect - that drinking too much alcohol can not only reduce a parent’s capacity to appropriately respond to children’s needs, but also make the drunken adult an active danger to the child.

One of the most worrying trends identified locally and nationally is a rise in the number of baby deaths connected with sleeping on a sofa with an adult who is under the influence of alcohol, the number of children left to care for their younger siblings and the impact of the example of parents’ drinking patterns on young people.

The number of victims of Sudden Infant Death Syndrome who were sleeping with a parent on a sofa has risen.

The campaign urges parents, and others with responsibility for children, to be aware of a range of potentially dangerous consequences if no adult remains sufficiently sober and aware of children’s needs or whereabouts.


In one year in Birmingham alone: 
  • 82% of babies who died from Sudden Infant Death Syndrome were sleeping with a parent at the time
  • 56% of these deaths were on a sofa; 44% in the parental bed.
  • 78% of the fatalities were associated with parental alcohol use at the time
  • while 44% involved parental drug use.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness / Education, training and future workforce / Person centred care
Benefit to NHS:
  • supportive of statutory safeguarding responsibilities through reduced risk of harm to children and young people
  • supportive of adult clinical services due to reduced risk of harm to adults through excessive alcohol consumption.
  • community cohesion
  • marketing and education resources for professionals eg. health visitors, school nurses.
Initial Review Rating
3.60 (2 ratings)
Benefit to WM population:
  • reduced risk of harm to children and young
  • reduced risk of harm to adults through excessive alcohol consumption.
  • community cohesion
Current and planned activity: 
A set of photographs has been commissioned depicting hard-hitting photographic case study scenarios based on real life evidence from serious case reviews and other reported incidents.

AVAILABLE TO OTHER TRUSTS FREE OF CHARGE - If you wish to use these in your organisation, please contact David Disley-Jones or MidTECH Innovations (www.midtech.org.uk).

A simple logo was designed and has been trade-mark protected with the IPO.
A set of posters has been produced which have been displayed in a variety of locations.
A set of aide memoire cards has been produced for use by professionals such as health visitors and school nurses to generate discussion and raise awareness.
Who's In Charge? has been licensed to British Armed Forces in Germany for use on military bases, in acknowledgement of the issue of alcoholic consumption among military families.

 
What is the intellectual property status of your innovation?:
The logo and the use of the phrase 'Who's in Charge?' (in certain contexts) has been trade-marked with the IPO.
The photographs are copyright BCHC/Roy Peters Photography.
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Co-Authors:
Read more
Hide details
David Disley-Jones 30/05/2017 - 16:05 Publish Login or Register to post comments
0
0
Votes
-99999

Active Campaigns